Jon Njardarson/
May 30, 2025, 17:44
Jon Njardarson: Top 200 Drug Poster for 2024 Based on Retail Sales
Jon Njardarson, Professor at the University of Arizona, shared a post on LinkedIn:
“We just posted online the Top 200 Drug Poster for 2024 based on retail sales. Brilliant efforts by my awesome graduate student, Hayden Leatherwood, in creating this year’s poster. Biologics and peptides are continuously increasing their presence and rank along with drug combinations.
I am still amazed how much the drug structure landscape has changed in 20 years, a testament to a creative and vibrant industry. Please visit our group website to download/print your free copy. Best regards from Tucson, Jon.”
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared this post, adding:
“For ADCs, 2023 ranks vs. 2024 ranks:
Enhertu 65 – 51
Padcev >200 – 73
Kadcyla 67 – 94
Trodelvy 162 – 146
Polivy 169 – 159
Total about $13 billion! The higher ranks (and sales) for some ADCs nicely reflect both the expansion of clinical indications and approval in earlier treatment settings.”
More posts featuring Raffaele Colombo.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 30, 2025, 17:44
May 30, 2025, 16:07
May 30, 2025, 16:01